Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KN026 alone or in combination for HER2-low or HER2-positive recurrent/metastatic breast cancer
CTR20192289Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Jan 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab, sponsored by Alphamab Oncology. Started Jan 2020; status: completed.
02
Drugs
anbenitamab
Beyond the preview
Go deeper on CTR20192289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192289.